Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Stern Adam KOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Milhous Alison TjosvoldOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Cohen Douglas JayOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Murphy KeithOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Gobel DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Joshi VaidehiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 15, 2023 (filed on Nov 17, 2023)Insider Name:Gobel DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-19,607Price:$1.62
Filings by filing date
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Stern Adam KOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Milhous Alison TjosvoldOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Cohen Douglas JayOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Murphy KeithOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Gobel DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
-
Nov 15, 2023 (filed on Nov 17, 2023)Insider Name:Gobel DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-19,607Price:$1.62
-
Nov 17, 2023 (filed on Nov 17, 2023)Insider Name:Joshi VaidehiOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:19,607Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | Suite 110, 6275 Nancy Ridge Drive SAN DIEGO CA 92121 |
Tel: | N/A |
Website: | https://organovo.com |
IR: | See website |
Key People | ||
Keith E. Murphy Executive Chairman of the Board, Principal Executive Officer, Corporate Secretary | Tom P. Hess President, Chief Financial Officer | Vaidehi Joshi Director - Discovery Biology, Director |
Business Overview |
Organovo Holdings, Inc. is a biotechnology company that focuses on building high fidelity, three-dimensional (3D) tissues that recapitulate various aspects of human disease. The Company uses these models to identify gene targets responsible for driving the disease and intends to initiate drug discovery programs around these validated targets. It is initially focusing on the intestine and has ongoing 3D tissue development efforts in ulcerative colitis (UC) and Crohns disease (CD). The Company uses its technology to build functional 3D human tissues that mimic various aspects of native human tissue composition, architecture, function, and disease. Its NovoGen Bioprinters are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters. Its 3D human tissue platform is multifaceted. |
Financial Overview |
For the nine months ended 31 December 2023, Organovo Holdings Inc revenues decreased 62% to $80K. Net loss increased 19% to $11.6M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Selling, general, and administrative exp increase of 25% to $6.4M (expense), Research and development expensesBala increase of 38% to $4.1M (expense). |
Employees: | 15 as of Jun 1, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $5.75M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.24M as of Dec 31, 2023 |
EBITDA (TTM): | -$19.50M as of Dec 31, 2023 |
Net annual income (TTM): | -$19.09M as of Dec 31, 2023 |
Free cash flow (TTM): | -$16.92M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 10,040,074 as of Feb 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |